CONTRAVISORY INVESTMENT MANAGEMENT, INC.
Position in LGND — Ligand Pharmaceuticals Inc
CIK 1365707
Norwell, MA
Position in LGND
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$647,352
+$244,059 QoQ
Shares Held
2,048
+1.4% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#229
of 411 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CONTRAVISORY INVESTMENT MANAGEMENT, INC. holds $10,005,629 across 11 Biotechnology names. LGND ranks #3 (6.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,147 | $6,327,060 | |
| 2 | MRNA |
Moderna, Inc.
|
24,218 | $1,695,986 | |
| 3 | LGND |
Ligand Pharmaceuticals Inc
This page
|
2,048 | $647,352 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
4,604 | $538,990 | |
| 5 | DNLI |
Denali Therapeutics Inc.
|
14,674 | $377,415 | |
| 6 | BEAM |
Beam Therapeutics Inc.
|
9,899 | $339,733 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
171 | $32,024 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
288 | $21,450 |
All Filings in LGND
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $647,352 | 2,048 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $403,293 | 2,020 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $384,946 | 2,036 | Shares | Sole | 2026-01-12 | |
| 2025-09-30 | $386,342 | 2,181 | Shares | Sole | 2025-10-09 | |
| 2025-06-30 | $257,030 | 2,261 | Shares | Sole | 2025-07-10 | |
| No filing history on record for this holder in this stock. | ||||||